Company Overview of Lux Biosciences, Inc.
Lux Biosciences, Inc., a biotechnology company, engages in the development and commercialization of medications for ophthalmic diseases in the United States and internationally. Its products comprise LUVENIQ, an oral form of calcineurin inhibitor voclosporin, which is used for the treatment of non-infectious uveitis; LX214, a topical formulation that contains mixed nanomicelles of voclosporin for ophthalmic use; LX212, a bioerodible polymer implant containing voclosporin; and LX213, a bioerodible/isotechnika implant. The company was incorporated in 2005 and is based in Jersey City, New Jersey.
3 Second Street
Harborside Financial Center Plaza 10
Jersey City, NJ 07302
Founded in 2005
Key Executives for Lux Biosciences, Inc.
Lux Biosciences, Inc. Key Developments
Similar Private Companies By Industry
|Bridge to Life, Ltd.||United States|
|Enobia Pharma Corp.||United States|
|Buffalo Clinical Research Center, LLC||United States|
|Biofocus Inc||United States|
|Sanofi Pasteur, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Madison, WI | Madison Area Technical CollegePosted: May 23
- Efland, NC | Orange County SchoolsPosted: May 22
- Cambridge, MA | ElsevierPosted: May 23
Sponsored Financial Commentaries
To contact Lux Biosciences, Inc., please visit www.luxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.